MedTrace Logo

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

NCT00789256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-10-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).

Conditions

Interventions

DRUG

Melphalan

Melphalan: 2mg orally, once daily

DRUG

Bortezomib

Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11

DRUG

Melphalan and bortezomib

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Principal Investigators

  • Marc Gautier, MD · Dartmouth-Hitchcock Medical Center

  • Jeffrey Bubis, DO · Integrated Community Oncology Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00789256 on ClinicalTrials.gov